Home » Clinical Trials » Leukemia » NCT05643742
NCT05643742

A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies

Study Summary

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

Want to learn more about this trial?

Request More Info

Interventions

CTX112BIOLOGICAL
CTX112 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)

Study Locations

FacilityCityStateCountry
University of KansasWestwoodKansasUnited States
Washington UniversitySt LouisMissouriUnited States
SCRISan AntonioTexasUnited States
University of UtahSalt Lake CityUtahUnited States
Royal Prince AlfredCamperdownNew South WalesAustralia
Alfred HealthMelbourneVictoriaAustralia
Sir Charles Gairdner HospitalNedlandsWestern AustraliaAustralia

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026